Hangzhou Tigermed Consulting Co., Ltd, a leading clinical contract research organization (CRO) in China, recently selected Oracle Health Sciences InForm to more efficiently develop, conduct and manage electronic data capture (EDC)-based clinical trials on behalf of its clients.
Being an existing user of Oracle Clinical for their paper trials, Tigermed selected Oracle Health Sciences InForm to extend its competitive edge in the local market and support international expansion with a trusted and highly scalable, leading clinical data management platform.
With its standardized feature sets, comprehensive data capture functionality and multi-language capabilities, Oracle Health Sciences InForm provides Tigermed with a robust solution to meet the needs of China’s clinical trial sponsors – while allowing for seamless expansion into the global marketplace.
“By adopting Oracle Health Sciences InForm, we will be positioned to support the growing number of clinical trials conducted in China, and their sponsors, with leading clinical data management capabilities,” said Wen Chen, vice president, Tigermed. “Further, with Oracle’s training and support through the Oracle CRO Advantage Program, we can maximize our investment in Oracle Health Sciences solutions – securing the confidence of a growing number of clinical trial sponsors.”
Oracle Health Sciences InForm’s comprehensive data review capabilities will enable Tigermed to gain better control over its data and generate efficiency and productivity gains in data management and remote monitoring.
Using Oracle Health Sciences InForm, Tigermed will be able to develop flexible source verification strategies that allow rapid changes to the source verification workload based on data quality.
In addition, Tigermed will be able to take advantage of Oracle Health Sciences Central Designer’s centralized study design environment to accelerate trial development and increase trial efficiency.
“With a heavy focus on growth, Tigermed requires a solution that will extend its clinical data management and EDC capabilities,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “Tigermed relies on Oracle Health Sciences’ world-class solutions, including Oracle Health Sciences InForm and Oracle Health Sciences Central Designer, to enable rapid trial set up, data accuracy, clinical trial productivity and informed decision making – helping Tigermed to gain the trust of both local and global trial sponsors.”
To differentiate its business and gain a competitive advantage, Tigermed joined the Oracle CRO Advantage Program – a program that provides a framework for driving CRO success with Oracle Health Sciences products through training, sales and marketing support and tools and regular communications on Oracle products and strategy.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.